The main objective of this core Is the enrollment of every patient AML and MDS referred to Washington University into the Tissue Acquisition and Clinical Database protocol of the GAML program project. Skin, oral mucosa, bone marrow, peripheral blood leukocytes and serum specimens collected from patients will be banked and processed by Core B, the Specimen Acquisition, Genomic, Transcriptomic, and Epigenetic Profiling Core, whereupon they will serve as the basis for genomic analyses outlined In Core C, to be utilized in Projects 1-4. This Clinical Core will also maintain and expand a comprehensive database that captures essential clinical, pathological, karyotypic, molecular, therapeutic, and outcomes data of enrolled AML and MDS patients, anonymously linked with the corresponding tissue specimens. The Clinical Core database will provide key clinical annotation that, in conjunction with gene expression data generated by Core B and DNA sequence data generated by Core C, which will be utilized by Projects 1-4. A.1.
Specific Aim 1 : We will prospectively collect and bank tissue for analysis at diagnosis, in remission, and at relapse from every patient referred to the Washington University Siteman Cancer Center with AML and MDS. A.2.
Specific Aim2 : We will maintain a comprehensive clinical leukemia database that will capture epidemiological data, disease-related characteristics, prognostic factors, therapeutic information, and outcomes data from all enrolled AML and MDS patients, with de-identified linkage to corresponding banked tissue specimens.
The specimens collected and the database maintained by Core A are essential to the success of Projects 1- 4 outlined in this proposal. These have served as a unique and invaluable resource both for this Program Project since Its inception, and for extramural projects (TCGA) as well.
|Engle, E K; Fisher, D A C; Miller, C A et al. (2015) Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia 29:869-76|
|Al-Hussaini, Muneera; DiPersio, John F (2014) Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Rev Hematol 7:439-64|
|Jacoby, M A; De Jesus Pizarro, R E; Shao, J et al. (2014) The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. Leukemia 28:1242-51|
|Sarkaria, S M; Christopher, M J; Klco, J M et al. (2014) Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro. Leukemia 28:2403-6|
|Miller, Christopher A; White, Brian S; Dees, Nathan D et al. (2014) SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol 10:e1003665|
|Klco, Jeffery M; Spencer, David H; Miller, Christopher A et al. (2014) Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25:379-92|
|Russler-Germain, David A; Spencer, David H; Young, Margaret A et al. (2014) The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25:442-54|
|Hughes, Andrew E O; Magrini, Vincent; Demeter, Ryan et al. (2014) Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet 10:e1004462|
|White, Brian S; DiPersio, John F (2014) Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer 120:1134-44|
|Grieselhuber, N R; Klco, J M; Verdoni, A M et al. (2013) Notch signaling in acute promyelocytic leukemia. Leukemia 27:1548-57|
Showing the most recent 10 out of 65 publications